ATH 14.3% 0.3¢ alterity therapeutics limited

Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-74

  1. 52 Posts.
    lightbulb Created with Sketch. 8
    At this market cap, to have a drug that has been objectively assessed via biomarkers (albeit not statistically significant yet) to be a disease modifying drug for a neurological disorder with no current treatment is as good as it gets imo. The 201 readout next year is going to be a watershed moment for MSA sufferers I think.

    This can be a US500 M net annual sales drug within 5 years if the science continues to play out....
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
-0.001(14.3%)
Mkt cap ! $15.96M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $11.18K 3.279M

Buyers (Bids)

No. Vol. Price($)
38 52064257 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 126697935 22
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.